Belumosudil + Ruxolitinib for Graft-versus-Host Disease

(BELRUX Trial)

This trial tests a new treatment for individuals with chronic graft-versus-host disease (cGvHD), a condition causing inflammation and organ damage after a stem cell or bone marrow transplant. It combines two oral drugs, ruxolitinib and belumosudil, to determine if they work better together for those unresponsive to standard steroid treatments. The goal is to provide better symptom control and improve quality of life for patients with moderate to severe cGvHD. Individuals who continue to experience cGvHD symptoms despite steroid treatment might be suitable candidates for this trial. As a Phase 2 trial, the research focuses on evaluating the treatment's effectiveness in an initial, smaller group, offering hope for improved outcomes.

Research has shown that using belumosudil and ruxolitinib together is generally safe for people with chronic graft-versus-host disease (cGvHD). Studies have found that this drug combination has low rates of serious side effects. In one study, two out of five patients developed infections, but none required hospitalization. Another study with 14 patients demonstrated that adding belumosudil to ruxolitinib was safe and appeared more effective together. Both drugs are well-tolerated and target different parts of the immune system, potentially controlling symptoms more effectively. Overall, the evidence suggests that this treatment is manageable for most patients.¹²³⁴⁵

Researchers are excited about the combination of Belumosudil and Ruxolitinib for treating graft-versus-host disease (GvHD) because it offers a new approach by combining two oral agents with unique mechanisms. While standard treatments like corticosteroids or calcineurin inhibitors target the immune system broadly, Ruxolitinib specifically inhibits the JAK1/2 pathways, which are key in inflammation, and Belumosudil targets ROCK2, a different pathway implicated in immune regulation. This dual-action approach not only provides a more targeted treatment but also has the potential to offer relief for patients who don't respond well to existing therapies.

Studies have shown that both ruxolitinib and belumosudil can help patients with chronic graft-versus-host disease (cGvHD) when used separately. Ruxolitinib reduces inflammation and improves symptoms in some patients. Belumosudil affects certain parts of the immune system, helping to reduce organ damage caused by cGvHD. In this trial, researchers are evaluating the effectiveness of using these two drugs together. Early signs suggest that combining these drugs might benefit patients who haven't responded well to other treatments, potentially offering more effective disease control.⁶⁷⁸⁹¹⁰